Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Metastatic Cancer Pancreas
Interventions: PF-03084014, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Aurora, Colorado • Rochester, New York

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more

Conditions: Insomnia
Interventions: PD 0200390, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Alzheimer Disease
Interventions: Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 37
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more

Conditions: Presbyopia
Interventions: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 40 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 10
States / cities: Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive Tumor, Progesterone Receptor Positive Tumor, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Focus Group, Text Message, Best Practice, Questionnaire Administration; Behavioral · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Sewell, New Jersey • Abington, Pennsylvania • Doylestown, Pennsylvania + 1 more

Conditions: Healthy
Interventions: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg, Paxil CR™ Tablets 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 1 Diabetes, Hyperglycemia, Postprandial
Interventions: Insulin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cocaine Use Disorder
Interventions: Cocaine, Placebo oral capsule, Zolmitriptan; Drug
Lead sponsor: William Stoops; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: COVID-19
Interventions: Lopinavir/Ritonavir 400 mg/100 mg, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Malignant Digestive System Neoplasm, Nausea and Vomiting
Interventions: Aprepitant, Dexamethasone, Dolasetron Mesylate, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions: AJ201; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Hematopoietic Stem Cell Transplantation, Graft Failure
Interventions: Emapalumab 3 mg/kg, Emapalumab 10 mg/kg; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-210, Mitomycin C, Gemcitabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 27
States / cities: Sun City, Arizona • Los Angeles, California • Lakewood, Colorado + 23 more

Conditions: Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions: Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab); Biological · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Drug Interactions
Interventions: Rosuvastatin, Rosuvastatin + BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Asthma
Interventions: Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more

Conditions: Obesity
Interventions: AMRA(r) Researcher Image reconstruction software, MRI: radiofrequency coils (Device Manufacturer: Siemens Medical Solutions USA, Inc.), MRI: Research pulse sequences (Device Manufacturer: NIH), MRI: Image Reconstruction and Analysis Software (Device Manufacturer: NIH), Bluetooth-enabled glucometer, Remote tailored-to-place coaching (TPC), Standard remote coaching (SRC), Run-in physical-activity monitoring, Ambulatory blood-pressure monitor, Polysomnography equipment; Device · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases
Interventions: Pecans, Usual Care; Drug · Other
Lead sponsor: Penn State University; Other
Eligibility: 25 Years to 70 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hepatocellular Carcinoma
Interventions: Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Trigeminal Neuralgia
Interventions: ExAblate Transcranial treatment; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle, BD NEXT 32G x 4mm pen needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Toms River, New Jersey • Asheville, North Carolina • Kingsport, Tennessee + 1 more

Conditions: Morning Sickness, Pregnancy Early
Interventions: Citrus-Based Aromatherapy, Mint-Based Aromatherapy, Spice-Scented Aromatherapy, Control; Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Franklin, Tennessee

Search by objective public record fields.

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes

Cocaine and Zolmitriptan

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19

Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

Efficacy and Safety Study in Subjects With Asthma

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

Cardiometabolic Effects of Pecans as a Snack

Trial Comparing PLA to HIGRT (PROVE-HCC)

MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia

Clinical Evaluation of BD NEXT Pen Needle

The Effect of Scent on Pregnancy Induced Nausea, Vomiting, and Quality of Life